Overview

Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the efficacy and safety of Neuromultivit (solution for injections) in treatment of vertebrogenic radiculopathy L5, S1 in comparison with standard therapy. The patients are randomised into two groups: standard therapy group and standard therapy plus Neuromultivit group.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Collaborator:
Valeant Russia, LLC
Treatments:
Clonidine
Diclofenac
Tizanidine